China Medical System Holdings Ltd. - B (02509.HK) announced its interim results for the six months ended in June, with revenue reaching 449.2 million yuan (same below). The loss narrowed from 0.258 billion yuan in the same period last year to 0.172 billion yuan, with a loss per share of 79 cents. No interim dividend will be paid.
《業績》荃信生物(02509.HK)中期虧損收窄至1.72億人民幣
Performance: Quanxin Biotech (02509.HK) narrowed its half-year loss to 0.172 billion RMB.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated